Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.8, Iss.3, 2004-06, pp. : 221-239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecularly targeted therapy in myeloid leukaemias

By Craddock Charles

Clinical Medicine, Vol. 7, Iss. 6, 2007-12 ,pp. : 632-635

Royal College Of Physicians

Access to resources Recommend Favorite

Targeting tyrosine-kinases in ovarian cancer

By Morotti Matteo Becker Christian M Menada Mario Valenzano Ferrero Simone

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1265-1279

Informa Healthcare

Access to resources Recommend Favorite

Receptor Tyrosine Kinases and Anticancer Therapy

Current Pharmaceutical Design, Vol. 11, Iss. 9, 2005-04 ,pp. : 1139-1149

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy

Current Drug Targets, Vol. 17, Iss. 14, 2016-11 ,pp. : 1687-1703

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: Targeting Neuregulin1 and HER Receptor Tyrosine Kinases for Therapy of Breast Cancer and Heart Failure

Current Pharmaceutical Design, Vol. 20, Iss. 30, 2014-09 ,pp. : 4854-4855

Bentham Science Publishers

Access to resources Recommend Favorite